{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"MEK inhibitor PD0325901"},{"type":"Synonym","name":"PD-0325901"},{"type":"CodeName","name":"PD 901"},{"type":"CASRegistryName","name":"391210-10-9"}],"definition":{"html":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","text":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors."},"drugInfoSummaryLink":null,"nciConceptId":"C52195","nciConceptName":"Mirdametinib","termId":456780,"name":"mirdametinib","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"mirdametinib"}],"links":null}